文献速递肿瘤 PET/CT神经核医学

GLP-1受体PET在惰性与侵袭性胰岛素瘤中的诊断表现

Glucagon-like peptide-1 receptor PET in indolent and aggressive insulinoma: Diagnostic performance, quantitative differences, and clinical implications.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-04

惰性胰岛素瘤灵敏度98.4%、特异度71.4%、准确率95.8%,侵袭性胰岛素瘤检出率显著较低(76.0% vs. 98.4%,P=0.002)。侵袭性亚组中GLP-1R阳性病灶数目独立预测低血糖控制不佳(OR=2.0,95%CI 1.1-3.7,P=0.027)。

要点

  • 68Ga-exendin-4 PET/CT对惰性胰岛素瘤诊断准确率高
  • 侵袭性胰岛素瘤GLP-1R PET检出率显著低于惰性肿瘤
  • 生长抑素受体PET/CT对侵袭性胰岛素瘤阳性率更高

核心结论

  • GLP-1R PET对惰性胰岛素瘤诊断准确率优异,但侵袭性疾病灵敏度降低。
  • 生长抑素受体PET/CT对侵袭性肿瘤检测更有效。
  • GLP-1R阳性肿瘤负荷可能作为低血糖控制的影像生物标志物。

研究设计与样本

  • 所有患者行68Ga-exendin-4 PET/CT,部分另行68Ga-DOTANOC PET/CT。
  • 以手术和活检病理为参考标准,患者分为惰性与侵袭性胰岛素瘤组。

主要发现

  • 惰性胰岛素瘤:灵敏度98.4%、特异度71.4%、准确率95.8%。
  • 侵袭性胰岛素瘤检出率76.0%,显著低于惰性的98.4%(P=0.002)。
  • 68Ga-DOTANOC PET/CT在侵袭性中阳性率92.0%,高于惰性的67.7%(P=0.047)。
  • 侵袭性亚组GLP-1R阳性病灶数目独立预测低血糖控制不佳(OR=2.0,95%CI 1.1-3.7,P=0.027)。

关键数值与推荐

  • 惰性胰岛素瘤68Ga-exendin-4 PET/CT:灵敏度98.4%、特异度71.4%、准确率95.8%。
  • 侵袭性vs惰性检出率:76.0% vs. 98.4%,P=0.002。
  • 68Ga-DOTANOC阳性率:侵袭性92.0% vs惰性67.7%,P=0.047。
  • GLP-1R阳性病灶数目预测低血糖控制不佳:OR=2.0,95%CI 1.1-3.7,P=0.027。

临床怎么用

  • 惰性胰岛素瘤首选GLP-1R PET/CT定位,准确性高。
  • 侵袭性胰岛素瘤应联合生长抑素受体PET/CT以提高检出。
  • GLP-1R阳性病灶数目可用于评估低血糖控制风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the diagnostic performance, quantitative characteristics, and clinical implications of Glucagon-Like Peptide-1 Receptor (GLP-1R) PET using 68Ga-exendin-4 in patients with indolent and aggressive insulinomas, and to refine its role in comprehensive disease assessment. METHODS: In this prospective study, patients presenting with hypoglycemia and fulfilling Whipple's triad were enrolled. All patients underwent 68Ga-exendin-4 PET/CT, and a subset also received 68Ga-DOTANOC PET/CT. The pathology of surgery and biopsy served as the reference standard. Patients were stratified into indolent and aggressive insulinoma groups. Diagnostic performance metrics were calculated, and logistic regression analysis was performed to identify predictors of hypoglycemia control. RESULTS: Ninety-six patients with suspected insulinoma were enrolled in this study (64 indolent, 25 aggressive insulinomas, and 7 non-insulinomas). For indolent insulinomas, 68Ga-exendin-4 PET/CT demonstrated a sensitivity of 98.4%, specificity of 71.4%, and accuracy of 95.8%. Detection rate for aggressive insulinomas was significantly lower than that for indolent tumors (76.0% vs. 98.4%, P = 0.002). Conversely, 68Ga-DOTANOC PET/CT demonstrated a higher positivity rate in aggressive insulinomas compared with indolent cases (92.0% vs. 67.7%, P = 0.047). In the aggressive subgroup, the number of GLP-1R-avid lesions independently predicted poor hypoglycemia control (OR = 2.0, 95% CI: 1.1-3.7, P = 0.027). CONCLUSION: GLP-1R PET provides excellent diagnostic accuracy for indolent insulinomas but has reduced sensitivity in aggressive disease. In contrast, somatostatin receptor PET/CT is more effective for detecting aggressive tumors. GLP-1R-positive tumor burden may serve as a potential imaging biomarker for hypoglycemia control, supporting the complementary roles of these modalities in insulinoma management.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Xu J, Liang Y, Xu X, et al. Glucagon-like peptide-1 receptor PET in indolent and aggressive insulinoma: Diagnostic performance, quantitative differences, and clinical implications. Eur J Nucl Med Mol Imaging. 2026. PMID: 42400625. doi:10.1007/s00259-026-08039-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。